ACTG Publications

TitleAuthorsDateJournalIssueVolume
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.Mitsuyasu, Ronald ; Gelman, Rebecca ; Cherng, Deborah Weng ; Landay, Alan ; Fahey, John ; Reichman, Richard ; Erice, Alejo ; Bucy, R Pat ; Kilby, J Michael ; Lederman, Michael M ; Hamilton, Carol D ; Lertora, Juan ; White, Becky L ; Tebas, Pablo ; Duliege, Anne-Marie ; Pollard, Richard B ; AIDS Clinical Trials Group 328 Study Team2007 Mar 26Arch Intern Med6167
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment.Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald ; AIDS Clinical Trials Group A5132 Team2011 JunJ Interferon Cytokine Res631
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).Kilby, J Michael ; Bucy, R Pat ; Mildvan, Donna ; Fischl, Margaret ; Santana-Bagur, Jorge ; Lennox, Jeff ; Pilcher, Chris ; Zolopa, Andrew ; Lawrence, Jody ; Pollard, Richard B ; Habib, Raphaelle El ; Sahner, David ; Fox, Lawrence ; Aga, Evgenia ; Bosch, Ronald J ; Mitsuyasu, Ronald ; Adult AIDS Clinical Trials Group A5024 Protocol Team2006 Dec 15J Infect Dis12194
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.Krishnan, Supriya ; Schouten, Jeffrey T ; Jacobson, Denise L ; Benson, Constance A ; Collier, Ann C ; Koletar, Susan L ; Santana, Jorge ; Sattler, Fred R ; Mitsuyasu, Ronald ; ACTG-ALLRT Protocol Team2011Oncology1-280
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.Sharaf, Radwa ; Lee, Guinevere Q ; Sun, Xiaoming ; Etemad, Behzad ; Aboukhater, Layla M ; Hu, Zixin ; Brumme, Zabrina L ; Aga, Evgenia ; Bosch, Ronald J ; Wen, Ying ; Namazi, Golnaz ; Gao, Ce ; Acosta, Edward P ; Gandhi, Rajesh T ; Jacobson, Jeffrey M ; Skiest, Daniel ; Margolis, David M ; Mitsuyasu, Ronald ; Volberding, Paul ; Connick, El2018 Aug 31J Clin Invest9128
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.Stapleton, Jack T ; Chaloner, Kathryn ; Zhang, Jingyang ; Klinzman, Donna ; Souza, Inara E ; Xiang, Jinhua ; Landay, Alan ; Fahey, John ; Pollard, Richard ; Mitsuyasu, Ronald2009 Mar 13AIDS523
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.Namazi, Golnaz ; Fajnzylber, Jesse M ; Aga, Evgenia ; Bosch, Ronald J ; Acosta, Edward P ; Sharaf, Radwa ; Hartogensis, Wendy ; Jacobson, Jeffrey M ; Connick, Elizabeth ; Volberding, Paul ; Skiest, Daniel ; Margolis, David ; Sneller, Michael C ; Little, Susan J ; Gianella, Sara ; Smith, Davey M ; Kuritzkes, Daniel R ; Gulick, Roy M ; Mello2018 Nov 05J Infect Dis12218
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald2010AIDS Res Ther7
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals.Hoffman, Risa M ; Jamieson, Beth D ; Bosch, Ronald J ; Currier, Judith ; Kitchen, Christina M R ; Schmid, Ingrid ; Zhu, Yuda ; Bennett, Kara ; Mitsuyasu, Ronald2011 OctJ Clin Immunol531